ReviewPathogens (Basel, Switzerland)2014
Animal models for influenza viruses: implications for universal vaccine development.
Review in Pathogens (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis.Scientific reports · 2018Pooled it
- Induction of innate cytokine responses by respiratory mucosal challenge with R848 in zebrafish, mice, and humans.The Journal of allergy and clinical immunology · 2019Trial
- Host-directed broad-spectrum immunotherapeutic strategy for respiratory infections: Heat-killed Caulobacter crescentus (HKCC) as an innate-immune based biotherapeutic/postbiotic.PLoS pathogens · 2026Article
- Exploring the Mechanism of Action of Chicoric Acid Against Influenza Virus Infection Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.International journal of molecular sciences · 2025Article
- Consensus-Guided Construction of H5N1-Specific and Universal Influenza a Multiepitope Vaccines.Biology · 2025Article
- An inactivated influenza D virus vaccine protects guinea pigs from infections and contact transmission caused by homologous challenge.Virology journal · 2025Article
- Effect of Inoculation Volume on a Mouse Model of Influenza Virus Infected with the Same Viral Load.Vaccines · 2025Article
- Review
- Flu-CED: A comparative transcriptomics database of influenza virus-infected human and animal models.Animal models and experimental medicine · 2024Article
- An effective vaccine against influenza A virus based on the matrix protein 2 (M2).Veterinary microbiology · 2024Article
- Swine influenza A virus isolates containing the pandemic H1N1 origin matrix gene elicit greater disease in the murine model.Microbiology spectrum · 2024Article
- Organoids in virology.Npj viruses · 2024Review
- Tonsil explants as a humanFrontiers in immunology · 2024Article
- The Effect ofMicroorganisms · 2023Article
- Quantitative measurement of influenza virus transmission in animal model: an overview of current state.Biophysical reviews · 2023Review
- Emerging Tick-BorneMicroorganisms · 2023Review
- Pathogenicity and anti-infection immunity of animal H3N2 and H6N6 subtype influenza virus cross-species infection with tree shrews.Virus research · 2023Article
- Common and species-specific molecular signatures, networks, and regulators of influenza virus infection in mice, ferrets, and humans.Science advances · 2022Article
- Development of a Mouse Model to Explore CD4 T Cell Specificity, Phenotype, and Recruitment to the Lung after Influenza B Infection.Pathogens (Basel, Switzerland) · 2022Article
- Role of sialylated glycans on bovine lactoferrin against influenza virus.Glycoconjugate journal · 2021Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Influenza virus infections are a significant cause of morbidity and mortality in the human population. Depending on the virulence of the influenza virus strain, as well as the immunological status of the infected individual, the severity of the respiratory disease may range from sub-clinical or mild symptoms to severe pneumonia that can sometimes lead to death. Vaccines remain the primary public health measure in reducing the influenza burden. Though the first influenza vaccine preparation was licensed more than 60 years ago, current research efforts seek to develop novel vaccination strategies with improved immunogenicity, effectiveness, and breadth of protection. Animal models of influenza have been essential in facilitating studies aimed at understanding viral factors that affect pathogenesis and contribute to disease or transmission. Among others, mice, ferrets, pigs, and nonhuman primates have been used to study influenza virus infection in vivo, as well as to do pre-clinical testing of novel vaccine approaches. Here we discuss and compare the unique advantages and limitations of each model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.